Duke spin-out Regado Biosciences has had to halt its clinical trial.
Regado Biosciences, a drug developer spun out of Duke University, witnessed its shares crash by 60% on July 3, 2014 when it had to halt its clinical trial to review safety data. The shares have not been recovering, hovering around $2.60 to $2.80 down from its all-time high of $14.10.
Regado was set up in 2001 and only celebrated its initial public offering in August 2013. It raised $43m then, at $4 a share – down from the targeted $5.…
